Loading...
Loading...
Jason Butler of JMP Securities initiated coverage of
Intra-Cellular TherapiesITCI on Tuesday with a Market Outperform rating and $26 price target.
“Intra-Cellular Therapies is focused on the development of ITI-007, a novel antipsychotic candidate currently in Phase 3 development for the treatment of schizophrenia,” Butler wrote in a note. The analyst adds that ITI-007 demonstrated “significant efficacy” in a 335-patient Phase 2 trial along with a “favorable safety profile.”
Butler anticipates the results of the Phase 3 trial in the fourth quarter 2015 while a second Phase 3 trial should begin in the first half of 2015. The analyst thinks the potential for the drug is “attractive” given a “strong mechanistic rationale and clinical results.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetInitiationAnalyst RatingsITI 007Jason ButlerJMP SecuritiesSchizophrenia
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in